title: Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
abstract: Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5%) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant). In the overall period, complete response rate for nausea and emesis in the triplet group was significantly higher than that in the doublet group (70% vs 35%; P = 0.027). Patients with no-emesis in the overall period were more frequently observed in the triplet group than in the doublet group (90% vs 65%; P = 0.058). All toxicities other than emesis were almost equivalent in both the groups. These results suggest that a triplet antiemetic prophylaxis may be optimal in the treatment with AI therapy for NRC-STS.
authors.affiliation: Department of Medicine and Biosystemic Science Department of Orthopaedic Surgery, Graduate School of Medical Sciences Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kusaba
authors.forename: Hozumi
authors.initials: H
authors.lastname: Kumagai
authors.forename: Kyoko
authors.initials: K
authors.lastname: Inadomi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Matsunobu
authors.forename: Katsumi
authors.initials: K
authors.lastname: Harimaya
authors.forename: Kotoe
authors.initials: K
authors.lastname: Takayoshi
authors.forename: Shuji
authors.initials: S
authors.lastname: Arita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ariyama
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
authors.forename: Eishi
authors.initials: E
authors.lastname: Baba
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000077608:Aprepitant; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant; D004317:Doxorubicin; D007069:Ifosfamide